The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesWB: Use at a concentration of 1-5 µg/ml.
This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.
Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
FunctionActs as an E3 ubiquitin-protein ligase. In the presence of the human cytomegalovirus (HCMV) protein UL144, participates in 'Lys-63'-linked auto-ubiquitination of TRAF6 resulting in the virally controlled activation of NF-kappa-B at early time of infection. The C-terminus can act as an allosteric activator of the cholera toxin catalytic subunit.
PathwayProtein modification; protein ubiquitination.
Sequence similaritiesIn the C-terminal section; belongs to the small GTPase superfamily. Arf family. Contains 1 B box-type zinc finger. Contains 1 RING-type zinc finger.
DomainThe RING-type zinc finger domain is responsible for E3 ubiquitin ligase activity.
Cellular localizationEndomembrane system. Golgi apparatus membrane. Lysosome membrane. Membrane-associated with the Golgi complex and lysosomal structures.